BioStem Technologies Q4 Earnings Call Highlights

Matuszewski highlighted publication of top-line results from a diabetic foot ulcer (DFU) clinical trial in the fourth quarter, saying the study showed “clear superiority” of BioStem’s BioREtain-processed product over standard of care. He said the company expects to publish additional DFU analyses in coming months and also expects to publish top-line results for its venous leg ulcer (VLU) study.In the fourth quarter of 2025, BioStem’s revenue consisted only of physician office customer sales, before the acqu ...